Roche Holding | ROG - Equity Capital And Reserves


Roche Holding reported CHF32.69B in Equity Capital and Reserves for its fiscal semester ending in June of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -5.94B 721M Jun/2026
Alcon AG USD 21.6B 538M Jun/2026
Almirall EUR 1.53B 43.26M Jun/2026
Amgen USD 11.69B 2.5B Jun/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
Bayer EUR 29.71B 863M Jun/2026
Biogen USD 19.04B 194.3M Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Eli Lilly USD 40.27B 6.39B Sep/2026
Fresenius EUR 19.7B 766M Jun/2026
Fresenius Medical Care EUR 13.53B 673.44M Jun/2026
Genmab DKK 5.96B 275M Jun/2026
Gilead Sciences USD 13.04B 1.3B Sep/2026
GlaxoSmithKline GBP 18.75B 1.11B Sep/2026
GRIFOLS EUR 7.98B 2.52B Jun/2026
Hikma Pharmaceutical USD 2.59B 42M Dec/2025
Lakefront Biotherapeutics EUR 3.26B 10.26M Jun/2026
Lonza CHF 9.13B 513M Dec/2025
Merck EUR 30.17B 430M Jun/2026
Merck USD 41.93B 3.94B Jun/2026
Novartis USD 41.95B 3.02B Jun/2026
Orion EUR 1.4B 129.5M Sep/2026
Pfizer USD 85.19B 4.91B Jun/2026
Philips EUR 11.48B 84M Jun/2026
Recordati EUR 2.13B 70.34M Jun/2026
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sanofi EUR 69.57B 3.24B Jun/2026
UCB EUR 10.87B 1.18B Dec/2025